Rex Graham's  Instablog

Rex Graham
Send Message
I’m CEO of San Diego Biotechnology Connection ( I have a M.S. degree (microbiology) from the University of Iowa and completed a one-year science journalism fellowship at MIT. I have been an award-winning science writer and editor for 30 years for newspapers,... More
My company:
San Diego Biotechnology Connection
My blog:
San Diego Biotechnology Connection
  • Scientists 'Gleeful' About Clinical Trial Of MediciNova's Treatment For Methamphetamine Addiction 0 comments
    Jun 26, 2013 4:23 PM | about stocks: MNOV

    Scientists who have evaluated a variety of drug candidates to treat methamphetamine addiction ((all of which failed in efficacy tests)) are "gleeful" about significant positive clinical results of a novel type of drug being development by San Diego biotech company MediciNova, Inc. (NASDAQ:MNOV).

    Quitting methamphetamine is extremely difficult. Withdrawal triggers toxicity in the brain that lasts from months to more than a year, leaving addicts feeling "foggy," slow and unable to continuously concentrate on many tasks. However, those taking MediciNova's ibudilast in a phase 1b clinical trial performed significantly better than a placebo group in a battery of mental tests that require accuracy and attention.

    The researchers conducting the trial at UCLA's Center for Behavioral and Addiction Medicine have tested every promising candidate drug for methamphetamine addiction, and Steven Shoptaw, a professor at the center, said ibudilast has emerged as the only one with significant positive results. The news is meaningful because there is no U.S. Food and Drug Administration (FDA) approved drug to treat methamphetamine addiction, and ibudilast is MediciNova's lead drug candidate. Ibudilast also is in trials to treat multiple sclerosis (MS).

    See why Kirk Johnson, CSO at MediciNova, UCLA researchers and investors are excited about what is likely to be the first approved blockbuster treatment for methamphetamine addiction. MediciNova's ibudilast has shown surprising good results in a phase 1b clinical trial. The larger Phase 2 trial starts in July 2013. (With video).

    Disclosure: I am long MNOV.

    Stocks: MNOV
Back To Rex Graham's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.